Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Achaogen, Inc.

Latest From Achaogen, Inc.

Spero's Oral Tebipenem HBr Stacks Up To IV Carbapenem In Phase III

Tebipenem HBr, a potential first oral carbapenem antibiotic, will be submitted to the US FDA under a rolling NDA in the first quarter of 2021 for complicated urinary tract infection and acute pyelonephritis.

Infectious Diseases Business Strategies

Big Pharma’s $1Bn Antibiotic Development Fund Offers ‘Breathing Room’ For Reimbursement Fix

Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.

Infectious Diseases Reimbursement

Big Pharma’s $1Bn Antibiotic Development Fund Offers ‘Breathing Room’ For Reimbursement Fix

Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.

Infectious Diseases Reimbursement

Stemline And Karyopharm Want More Time At EMA

A number of companies with marketing applications at the later stages of the EU review process are seeking extra time to address remaining concerns the European Medicines Agency’s drug evaluation committee, the CHMP, has about their filings.

Europe Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register